Next Article in Journal
Phenolic Acid Functional Quaternized Chitooligosaccharide Derivatives: Preparation, Characterization, Antioxidant, Antibacterial, and Antifungal Activity
Previous Article in Journal
New Fusarin Derivatives from the Marine Algicolous Fungus Penicillium steckii SCSIO41040
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Multicopy Chromosome Integration and Deletion of Negative Global Regulators Significantly Increased the Heterologous Production of Aborycin in Streptomyces coelicolor

1
Department of Marine Biological Science & Technology, College of Ocean and Earth Sciences, Xiamen University, Xiamen 361102, China
2
State-Province Joint Engineering Laboratory of Marine Bioproducts and Technology, Xiamen University, Xiamen 361102, China
3
Xiamen City Key Laboratory of Urban Sea Ecological Conservation and Restoration, Xiamen University, Xiamen 361102, China
4
Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China
5
National Technology Innovation Center of Synthetic Biology, Tianjin 300308, China
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2023, 21(10), 534; https://doi.org/10.3390/md21100534
Submission received: 13 September 2023 / Revised: 10 October 2023 / Accepted: 11 October 2023 / Published: 13 October 2023
(This article belongs to the Special Issue Metabolomic Study of Marine Streptomyces)

Abstract

:
Aborycin is a type I lasso peptide with a stable interlocked structure, offering a favorable framework for drug development. The aborycin biosynthetic gene cluster gul from marine sponge-associated Streptomyces sp. HNS054 was cloned and integrated into the chromosome of S. coelicolor hosts with different copies. The three-copy gul-integration strain S. coelicolor M1346::3gul showed superior production compared to the one-copy or two-copy gul-integration strains, and the total titer reached approximately 10.4 mg/L, i.e., 2.1 times that of the native strain. Then, five regulatory genes, phoU (SCO4228), wblA (SCO3579), SCO1712, orrA (SCO3008) and gntR (SCO1678), which reportedly have negative effects on secondary metabolism, were further knocked out from the M1346::3gul genome by CRISPR/Cas9 technology. While the ΔSCO1712 mutant showed a significant decrease (4.6 mg/L) and the ΔphoU mutant showed no significant improvement (12.1 mg/L) in aborycin production, the ΔwblA, ΔorrA and ΔgntR mutations significantly improved the aborycin titers to approximately 23.6 mg/L, 56.3 mg/L and 48.2 mg/L, respectively, which were among the highest heterologous yields for lasso peptides in both Escherichia coli systems and Streptomyces systems. Thus, this study provides important clues for future studies on enhancing antibiotic production in Streptomyces systems.

1. Introduction

Aborycin is a class I lasso peptide and was first isolated from Streptomyces sp. SP9440 as a novel anti-HIV metabolite with the origin name RP 71,955 [1,2]. It was independently rediscovered from soil S. griseoflavus Tü 4072 as an antibiotic [3], then from deep-sea Streptomyces sp. SCSIO ZS0098 as an anti-infective natural product [4] and from marine sponge-associated Streptomyces sp. MG010 as an antibacterial marker for screening gain-of-function mutants [5]. It was also predicted to be expressed in the mangrove soil strain Streptomyces sp. EMB24 [6]. Aborycin has a typical lasso topology in which the N-terminal 9 amino acids form a macrocyclic ring, and the C-terminal 12 amino acids form a tail that folds back and threads through the ring [2]. Two disulfide bonds between the ring and the tail further increase the structural stability and distinguish class I lasso peptides from others [7,8].
Lasso peptides are a growing class of bioactive bacterial peptides with unique lasso topology, which differentiates them from other members within the much larger ribosomally synthesized and post-translationally modified peptide (RiPP) superfamily [9,10]. The compact and constrained topology endows most lasso peptides with remarkable thermal and proteolytic stability and favors peptide–protein interactions, accounting for the diverse biological activities of lasso peptides, mainly as enzyme inhibitors and receptor antagonists [7,11]. Robust scaffolds of lasso peptides have attracted attention towards drug development, such as epitope grafting [12], the incorporation of noncanonical amino acids [13] and protein fusion [14]. While these modifications provide the opportunity to develop novel biological activities with therapeutic potential, they always lead to lower production levels [15]. Moreover, genome mining approaches have greatly accelerated lasso peptide discovery in recent years. Since the first lasso peptide was isolated by genome mining in 2008 [16], the number of lasso peptides discovered by such approaches has steadily increased [11]. By applying the RODEO algorithm, >1400 lasso peptide biosynthetic gene clusters (BGCs) were identified from DNA sequence databases, a great increase over the previously known numbers [17]. Although lasso peptide BGCs are widely distributed among bacteria, only approximately 80 lasso peptides were previously characterized [18]. Therefore, both drug development and functional characterization require effective production systems to explore this rich source of lasso peptides and their modifications.
The heterologous production of lasso peptides in E. coli often provides higher yields than the use of native producers. However, this production advantage in E. coli seems to be confined to lasso peptides from Proteobacteria and is less viable for clusters from other phyla [11,15]. Specially, inefficiency in expressing genes with high GC content, the lack of metabolic precursors and the lack of detoxification mechanisms are the main weakness of the E. coli system in terms of expressing natural products from actinomycetes [19,20]. Recently, Streptomyces hosts, especially S. coelicolor, S. lividans and S. albus, have shown significant potential for producing lasso peptides from actinobacteria [17,21,22]. Several technological advances have also been achieved for Streptomyces systems, such as CRISPR/Cas9 genome editing technology [23,24] and the multiplexed site-specific genome engineering (MSGE) method [25]. Genome editing offers a rapid way to modify regulatory elements involving secondary metabolism and therefore impact heterologous production. The MSGE method led to the successful development of a panel of S. coelicolor heterologous hosts, in which up to five copies of BGCs could be integrated into the specific sites of the host chromosome in a single step, leading to significant yield improvements [25]. In our previous study, an aborycin BGC was identified from a marine sponge-associated Streptomyces sp. HNS054 [5]. This provided an opportunity to produce this lasso peptide heterologously in Streptomyces systems. Thus, in this study, a Streptomyces system for aborycin production that is compatible with up-to-date technologies was established. By increasing the integrated copy numbers of the aborycin BGC in the host chromosome and by deleting the negative global regulatory genes involved in secondary metabolism by genome editing, the production of aborycin was significantly improved. This study provides a useful reference to improve Streptomyces systems for the production of lasso peptides and their modifications and thus benefits drug development and functional characterization.

2. Results

2.1. General Information on the Aborycin Gene Cluster from Streptomyces sp. HNS054

As previously reported [5], the aborycin gene cluster gul (named after Gulei Town, where the host marine sponge was collected from its coastal sea) from marine sponge-associated Streptomyces sp. HNS054 consists of 14 ORFs spanning an approximately 12 kb region from gulR1 to gulR2 (Figure 1). Sequence alignment showed that the DNA sequence of this region shares 98% identity to the aborycin gene cluster abo from Streptomyces sp. SCSIO ZS0098 [4]. The gul cluster also shows high identity to the siamycin-I gene cluster msl from Streptomyces sp. M-271 [26] in gene sequence and gene organization (Figure 1). GulA encodes a 42-residue peptide with a leader peptide at its N-terminus and a 21-residue core peptide (CLGIGSCNDFAGCGYAVVCFW) at its C-terminus. The primary and secondary structures of aborycin and siamycin-I are almost the same, except that the residues at the 4th and 17th positions are switched (Figure 1). Due to the high similarity between aborycin and siamycin-I, commercial reagents of siamycin-I could be used as a reference to locate the high-performance liquid chromatography (HPLC) signal of aborycin.

2.2. Cloning of the Gul BGC and Construction of Strains for Heterologous Expression of Aborycin

The cloning procedure of the gul BGC is shown in Figure S1. The 14 kb fragment containing the gul BGC was amplified from Streptomyces sp. HNS054 by high-fidelity PCR and subsequently cloned and inserted into the integrative vector pSAT209, yielding pSAT-GUL (Figure S2). The plasmid was fully sequenced, and the results confirmed that no mutation occurred within the plasmid frame nor the gul ORFs. Then, the plasmid pSAT-GUL was transferred to S. coelicolor strains M1146, M1246, M1346, M1446 and M1546 by conjugation. As a blank control, the empty plasmid pSAT209 was also transferred to S. coelicolor M1146. The numbers of successful attP-attB recombinations in exconjugants were determined by PCR. The results showed that strains M1146::gul (Figure S3A), M1246::2gul (Figure S3B) and M1346::3gul (Figure S3C) were successfully constructed. However, four-copy and five-copy integrations were unsuccessful after four rounds of conjugation and screening.

2.3. Extraction and Detection of Aborycin

With siamycin-I as the control, the M1346::3gul strain was used to test whether aborycin was successfully produced. Aborycin was extracted, as shown in Figure 2A. The butanone extract had an HPLC signal at 23.2 min, which was the same as the signal of siamycin-I (Figure 2B). In the following test of the macroporous adsorption resin method, the AB-8 resin showed high enrichment efficiency for aborycin that was equivalent to that of the butanone method. Mass spectrum analysis confirmed that a substance with a relative molecular mass of m/z = 1082.43 (z = 2) accounted for the majority of the composition at the 23.2 min peak of the AB-8-enriched samples (Figure 2C). The MS data of this substance were perfectly matched to the aborycin data from a previous report [5]. Thus, two facts were confirmed by these tests: First, the M1346::3gul strain can express aborycin. Second, compared with the butanone method, the AB-8 resin method offered a safer, easier and cheaper method to enrich aborycin from the fermentation supernatant. This method was thus applied in the following quantification studies: After pure aborycin was isolated from 5.6 L of culture broth containing the M1346::3gul strain, a precise standard curve of concentrations to the HPLC peak areas of aborycin was obtained (Figure 2D). By applying this curve, aborycin production from different strains or conditions could be quickly quantitated by HPLC. The 1H NMR spectral data of aborycin were also obtained to confirm the structure (Figure S4).

2.4. Yield Comparison among Different Strains

Titers of aborycin from different strains are shown in Figure 3. Adding the supernatant and mycelial products, the native HNS054 strain average yielded 4.9 ± 2.6 mg/L aborycin. No aborycin signal was detected from the blank control M1146::pSAT209 and the one-copy strain M1146::gul. Signals became obvious for the M1246::2gul and M1346::3gul strains, which had average titers of 1.8 ± 1.0 mg/L and 10.4 ± 1.6 mg/L, i.e., 0.4 times and 2.1 times that of the native strain, respectively. Both supernatant and mycelia contributed to the production, accounting for approximately 38 percent and 62 percent, respectively.
Then, the M1346::3gul strain was selected for genetic modification to verify whether aborycin production could be further improved by deleting negative regulatory genes (Table 1), which were reported to act at higher levels of the gene-regulatory networks to control secondary metabolism, whose knockout mutants always resulted in an increase in secondary metabolism. The ΔphoU, ΔwblA, ΔSCO1712, ΔorrA and ΔgntR mutants were successfully constructed (Figures S5 and S6). A titer study showed that the aborycin production of the M1346::3gul ΔphoU strain was 12.1 ± 0.7 mg/L, which was slightly higher than that of the M1346::3gul strain but not significantly different (p > 0.05). The ΔwblA strain was significantly (p < 0.01) higher than the M1346::3gul strain, with a titer of 23.6 ± 10.2 mg/L, i.e., 4.8 times that of the native strain or 2.3 times that of the strain before wblA knockout. Greater improvements were displayed in the ΔorrA and ΔgntR mutants, which had titers of 56.3 ± 18.0 and 48.2 ± 15.1 mg/L, respectively (Figure 3).

3. Discussion

In this study, efforts were made to use the Streptomyces system for the heterologous production of aborycin. First, the cloning procedure was simplified. The 14 kb genomic fragment containing the gul gene cluster was amplified by high-fidelity PCR, and sequencing confirmed its accuracy. High-fidelity PCR techniques have been developed to amplify long DNA fragments with lengths as long as 15–20 kb. The cloning of RiPP gene clusters could benefit from these developments because a large portion of RiPP gene clusters have lengths below 15 kb (Table S3). In a recent review on newly discovered RiPPs, out of the 33 listed gene clusters, 25 (76%) had lengths below 15 kb ([32], Table S4). Second, to facilitate foreign DNA integration following genome editing, the integrative vector pSET152 was modified to pSAT209 to prevent challenges related to antibiotic resistance. Third, the extraction of aborycin from the supernatant was optimized. Aborycin is a peptide with amphiphilic characteristics and thus has reversible affinity to certain macroporous adsorption resins. In this case, AB-8 resin was found to be such a resin, adsorbing aborycin in a water solution and desorbing it in methanol. The optimal AB-8 resin method condition is that the supernatant and AB-8 resin are 10:1 (v/v) mixed for 4 h to overnight, and then the resin is washed with a 5 × resin volume of 10% methanol following the desorption of the aborycin from the resin by a 2 × resin volume of methanol for 1 h. Compared with the butanone method [4,5], the AB-8 resin method recovered a majority of the aborycin from the supernatant with minimal organic solvent and minimal labor. The desorbed extract is also much cleaner than the butanone extract. By simply adsorbing and desorbing, approximately 40% of the total production was recovered from the culture supernatant. A similar situation occurred with the heterologous expression of sviceucin, where approximately 1/3 of the product was released in the culture supernatant [21]. Large-scale production would discard the supernatant because of the high cost of solvent extraction. With this optimization, the product in the supernatant could be recovered at a low cost. We speculated that this theory and operation could be applied to other RiPPs due to their peptide nature. Finally, the multiple chromosomal integration of foreign gene clusters following CRISPR/Cas9 genome editing was successfully achieved, and the best case resulted in a 25-fold increase in aborycin production compared to the native strain.
Multiple chromosomal integration of foreign BGC was proven to be a mature technique to increase heterologous expression. The approach was successfully demonstrated in S. coelicolor [25], S. albus J1074 [33] and S. lividans [34]. In this study, one-copy integration showed no signal, while three-copy integration showed a 2.1-fold increase compared to the native strain. However, more advanced techniques were needed to obtain four- or five-copy integration in one single step. In our attempts to transfer other BGCs into these M1146-M1546 hosts, the number of exconjugants decreased rapidly with increasing integrated copy number. It was previously speculated that a high copy number of chromosomal integration caused the accumulation of target products, endangering bacterial growth [25]. However, the titer of aborycin was further improved 5.4-fold by orrA gene knockout, implying that the Streptomycete actually tolerates higher concentrations of aborycin.
CRISPR/Cas-based genome editing tools provide swift, accurate and traceless ways to modify the genomes of Streptomyces [35]. A straightforward way to exploit the CRISPR/Cas9 tools was to delete negative regulator genes. This study proposed deleting genes that were reported to have a negative impact on secondary metabolism at a high level of the regulation networks. Five mutants, ΔphoU, ΔwblA, ΔSCO1712, ΔorrA and ΔgntR, were successfully constructed from the M1346::3gul strain.
Although the detailed function of the phoU gene was unclear, it was speculated to be involved in the pho regulon, which responds to phosphate starvation. PhoR senses such conditions, and then PhoP is phosphorylated following PhoP-P binding to specific sequences named PHO boxes, thus activating or repressing a set of genes [36]. Under phosphate starvation conditions, the ΔphoU mutants showed an approximately six-fold increase in the production of actinorhodin [27]. Our study showed that aborycin production in the ΔphoU mutants was not significantly improved from that in the strain before mutation when strains were cultured in R5 medium. Moreover, the growth of the ΔphoU mutants on MS-agar was retarded in a 9-day morphology observation (Figure 4). This type of the mutant requires more optimization before it can be applied in antibiotic production.
The wblA gene was reported as a pleiotropic downregulator of antibiotic biosynthesis in S. coelicolor. ΔwblA mutants exhibited a defect in sporulation, achieved higher biomass than the wild type, and overproduced secondary metabolites [37]. Overproduction of antibiotics by disruption of the wblA orthologs was also observed in other Streptomyces bacteria [38]. This study confirmed that the production of aborycin in the ΔwblA mutant was significantly improved by two-fold. Higher growth and defects in sporulation were also observed (Figure 4).
SCO1712 is a member of the TetR family. TetR family transcriptional regulators are among the most common prokaryotic transcriptional regulators. When SCO1712 was overexpressed or disrupted, ACT production decreased or increased compared with that in S. coelicolor M145, respectively, suggesting that SCO1712 is a pleiotropic downregulator of antibiotic biosynthesis in S. coelicolor [29]. It was further speculated that there is a synergistic effect between SCO1712 and precursor flux pathways in antibiotic production [39]. Unfortunately, in this study, after SCO1712 knockout, the production of aborycin decreased significantly. This provides ideas for future optimizations of precursor flux pathways or mediums for this mutant.
OhkA (SCO1596)—OrrA (SCO3008) is a group of prokaryotic two-component regulatory systems with highly similar transcriptomic features. ΔorrA mutants lead to the significant overproduction of antibiotics and the downregulation of the bld, chp, rdl, and wbl genes associated with morphological development [30]. Correspondingly, we found that ΔorrA mutants overproduced approximately 4.4-fold more aborycin than the strains before mutation (Figure 3). Their morphological development was also similar to that of the ΔwblA mutants (Figure 4). These results implied that the OrrA regulatory system likely covered the wbl regulatory system and controlled a wider range of resources for antibiotic production.
The bacterial GntR family is one of the most abundant groups of helix-turn-helix transcription factors that respond appropriately to metabolite microenvironments [40]. It was reported that deletion of a GntR-like gene allowed for platensimycin and platencin overproduction in S. platensis [41]. GntR (SCO1678) of S. coelicolor encodes a repressor protein to control the gluconate operon, which enables Streptomyces to utilize gluconate in the media [31]. No obvious evidence has linked GntR (SCO1678) to antibiotic overproduction to date. Interestingly, both the overproduction of aborycin (Figure 3) and overgrowth (Figure 4) were observed from the ΔGntR mutants in this study. No additional gluconate was added to the R5 or MS-agar media to obtain these results. These observations provide a significant gene that is worthy of further study to discover underlying metabolic regulatory mechanisms.
To further improve the production of aborycin, we attempted to double knockout the genes orrA and gntR. It was difficult to obtain enough spores from the ΔorrA strains. Thus, we tried to knock out the orrA gene from the M1346::3gul ΔgntR strain. The cloning process was difficult, and positive clones showed contradictory yields. We reason it in part to genetic instability, which might result from unknown genetic changes by one round of multi-sites of attP/attB recombination and two rounds of Cas9-based CRISPR. Thus, the cloning strategy should be carefully planned to achieve double knockout or triple knockout. It could be feasible that before the integration of the heterogeneous BGCs, stable S. coelicolor M1346-based double-knockout or triple-knockout hosts should be constructed by one round of multiplex genome editing [23,25] to reduce genetic instability risks, which might be brought from two or more rounds of CRISPR.
Although great production was achieved by these genetic modifications, we believe the Streptomyces systems could be further improved. With more global regulators that govern secondary metabolism being characterized [42], it is worth manipulating them one by one to obtain further knowledge.

4. Materials and Methods

4.1. Strains, Plasmids and Primers

The strains and plasmids used in this study are listed in Table S1, and the primers used in this study are listed in Table S2. The construction of the related vectors is shown in Figures S1 and S2.

4.2. Construction of Heterologous Expression Strains to Produce Aborycin

Foreign DNA integration could be fulfilled by the integrative plasmid pSET152 [43], and genome editing could be executed by the suicide plasmid pKCcas9 [24]. However, both vectors contain the apramycin resistance gene aac(3)IV. To achieve BGC integration following genome editing, the antibiotic-resistance markers between the two genetic manipulations should be different. Thus, the aac(3)IV gene in pSET152 was replaced by the ampicillin resistance gene bla from the pUC57 plasmid and the thiostrepton resistance gene tsr from the pGM1190 plasmid. The resulting plasmid was named pSAT209 (Figure S1). The Genomic DNA of Streptomyces sp. HNS054 was extracted from the later logarithmic phase cells using a bacterial genomic DNA extraction kit (Cat # DP2001, Biotake, Beijing, China). Using primers 054LasF and 054LasR, a 14 kb DNA fragment containing the gul BGC (located at 15932–29864 nt of GenBank: AC003_RS35325) was amplified from the Streptomyces sp. HNS054 genome (Assembly: GCF_001044185.1). After gel purification, the gul fragment was assembled with EcoRV-linearized pSAT209 using a one-step cloning kit (Cat # C113, Vazyme, Nanjing, China). The resulting vector pSAT-GUL (Figure S1) was sequenced to confirm the accuracy. Then, it and the control plasmid pSAT209 were transferred into E. coli ET12567/pUZ8002 competent cells and conjugated into S. coelicolor M1146-M1546 hosts by standard protocols [44]. Exconjugants were randomly picked to check attP-attB recombination by PCR with the following primers: The forward primer ID-oriT-fw targets a position approximately 400 bp upstream of the attP locus in the vector pSAT-GUL. The reverse primers, ID-native-attB-Rev, ID-CPK-attB-Rev, ID-RED-attB-Rev, ID-CDA-attB-Rev and ID-ACT-attB-Rev, each target a position downstream of an individual attB locus in the S. coelicolor M1546 genome. The integrated copy number of the gul gene cluster in the host genome was determined by the number of positive attP-attB recombinations [25].

4.3. Gene Knockout in S. coelicolor M1346::3gul by the CRISPR/Cas9 Method

The phoU (SCO4228), wblA (SCO3579), SCO1712, orrA (SCO3008) and gntR (SCO1678) genes (Table 1) in S. coelicolor M1346::3gul were independently knocked out by the CRISPR/Cas9 genome editing method [24]. To generate the ΔphoU mutant, the sgRNA expression cassette (f1 fragment) was PCR amplified with the plasmid pKCcas9dO as the template and f1J01-fwd/f1gRNA-R as primers. The upstream (f2 fragment) and downstream (f3 fragment) regions of the phoU gene were PCR amplified with the primer pairs f2J01-fwd/rev and f3J01-fwd/rev, respectively. Then, three DNA fragments were assembled by overlapping PCR using primers f1J01-fwd and f3J01-rev. The resulting DNA fragment was cloned and inserted into pKCCas9 using a one-step cloning kit (Cat # C113, Vazyme, Nanjing, China) to yield pKCCas9-dJ01. The obtained plasmid was introduced into the M1346::3gul strain by conjugal transfer. The correct knockouts were verified by PCR using primers ID-dJ01-fwd/rev. By using the J04, J05, J07 and J08 sets of primers and the same procedure, pKCCas9-dJ04, -dJ05, -dJ07 and -dJ08 were generated and yielded the ΔwblA, ΔSCO1712, ΔorrA and ΔgntR mutants after successful conjugation into the M1346::3gul strain, respectively. The positions of the spacers, primers and target genes are shown in Figure S5.

4.4. Metabolite Analysis

The wild-type Streptomyces sp. HNS054 and the S. coelicolor strains were grown on MS solid medium to achieve sporulation. Approximately 108 spores (or 40 μL mycelia store) were transferred to 40 mL R5 medium with appropriate antibiotics and cultured at 200 rpm and 28 °C for 3 days as the seed solution. Ten milliliters of the seed was transferred to 500 mL of R5 medium and cultured at 200 rpm and 28 °C for 9 days to complete the fermentation. Aborycin was extracted, as shown in Figure 2A. The fermented broth was centrifuged to separate the supernatant from the mycelia and then independently extracted. The supernatant was extracted by two methods. The first method was butanone extraction three times, and then the butanone phase was concentrated by rotary evaporation. Then, four macroporous adsorption resins, AB-8, DC201-C, NK-9 and D101 (Hecheng New Material, Zhengzhou, China), were tested for their aborycin recovery efficiencies. The AB-8 resin had a high enrichment ratio for aborycin (Figure 2B); therefore, AB-8 was used as the second method to extract aborycin. Because the AB-8 resin method was safer, easier and cheaper, all aborycin titers of the supernatants in this study were obtained by this method. The mycelium was extracted three times with 300 mL methanol and then concentrated by rotary evaporation. Extracts from both the supernatant and mycelia were adjusted to a final concentration of approximately 5 mg/mL in methanol and filtered with 0.22 µm filter membranes before HPLC or LC—MS analysis. Analytical HPLC was performed using a Shimadzu Prominence LC-20A (Shimadzu, Tokyo, Japan) with a 2.6 × 250 mm Ultimate XB-C18 column (Welch, Shanghai, China). The elution conditions were 1% solvent B for 0–7 min and then a linear gradient to 95% solvent B (solvent B: 0.1% formic acid in CH3CN; solvent A: 0.1% formic acid in H2O) for 7–30 min at a flow rate of 1 mL/min and monitored at 277 nm. To locate the aborycin signal, the commercial siamycin-I reagent (Adipogen Life Sciences, San Diego, CA, USA) was used as the control. Because the amino acid sequences between aborycin and siamycin-I were the same except the switched residues at the 4th and 17th positions (Figure 1), it is reasonable to expect the HPLC signal position of aborycin to be slightly different from that of siamycin-I. LC—MS analysis was performed using a Q Exactive spectrometer (Thermo Scientific, Waltham, MA, USA) with the same elution program as HPLC. The software MZmine 2 [45] was used to assess the chromatograms.

4.5. Purification of Aborycin, the Calibration Curve and 1H-NMR Spectra

A 5.6 L culture broth of the M1346::3gul strain was prepared as described in the previous section. The crude extract was enriched by the AB-8 resin method from the supernatant and then purified by semipreparative HPLC with a YMC-PACK ODS-A column (10 × 250 mm, φ 5 μm, YMC, Kyoto, Japan). F1–F4 fractions near the target position were collected, and the F2 fraction was determined by analytical HPLC to be the major fraction containing aborycin. Then, approximately 22 mg of the F2 fraction was obtained after rotary evaporation. Ten milligrams of the F2 fraction was dissolved in 2 mL of methanol, and analytical HPLC was run as described in the previous section. The 23.2 min peaks were collected and concentrated to approximately 4 mg of pure aborycin in the form of a white powder. A methanol solution of aborycin was prepared with a precise concentration of 1.00 mg/mL and then diluted to a series of concentrations. These dilutions were subjected to analytical HPLC, and the 23.2 min peak areas were recorded. A standard curve of concentrations to HPLC peak areas of aborycin was then constructed (Figure 2D), and the following formula was deduced.
y = 4.970 x + 0.046 (R2 = 0.999)
where y (106∙mAU∙min) is the peak area of the HPLC signal of aborycin, and x (mg/mL) is the concentration.
Approximately 3.5 mg of aborycin was dissolved in 500 μL DMSO, and the 1H NMR (600 MHz) spectra of aborycin were obtained using a Bruker Avance III HD 600 MHz spectrometer (Bruker, Billerica, MA, USA).

5. Conclusions

This study demonstrated improvements in the S. coelicolor system for aborycin overproduction. The maximum shake flask titer was over 50 mg/L, which is comparable to the best examples of E. coli systems or Streptomyces systems for lasso peptide heterologous expression [15]. We confirmed that increasing the copy number of chromosome integration and disrupting the negative global regulators governing secondary metabolism were effective ways to improve antibiotic production in S. coelicolor systems. GntR (SCO1678) was proposed to be a significant target that is worthy of further studies on metabolic regulatory mechanisms. The optimized extraction method, which could efficiently recover aborycin from the supernatant, also contributed to the total titer. Due to the similar chemical properties of RiPPs to aborycin, this tactic is also suitable for the development of other RiPP relatives. By applying these modifications to Streptomyces systems, the drug development and functional characterization of new lasso peptides from genome mining will be greatly improved.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/md21100534/s1, Figure S1: Construction of the integrative vector for aborycin expression; Figure S2: Cloning of the gul gene cluster; Figure S3: PCR validation of gul cluster integration in the attB loci. Figure S4: 1H NMR (600 MHz) spectrum of aborycin in DMSO. Figure S5: CRISPR/Cas9 constructions of the five gene-knockout mutants from M1346::3gul; Figure S6: PCR screening for positive mutants; Table S1: Information of plasmids and strains; Table S2: Primer sequence used in this study; Table S3: The length of RiPP biosynthetic gene clusters; Table S4: RiPP examples reported by Montalbán-López et al [46,47,48,49,50,51,52,53,54,55,56].

Author Contributions

Conceptualization, J.-Y.L. (Jia-Yi Li) and J.C.; methodology, J.-Y.L. (Jia-Yi Li), J.-Y.L. (Jun-Yu Liang) and Z.-Y.L.; validation, Y.-Z.Y.; investigation, J.C. and Z.-Y.H.; resources, J.Z. and J.C.; writing—original draft preparation, J.-Y.L. (Jia-Yi Li) and J.C.; writing—review and editing, J.-Y.L. (Jia-Yi Li) and J.C.; supervision, J.C. and Z.-Y.H.; project administration, J.C.; funding acquisition, J.C. and Z.-Y.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Key R&D Projects of Hainan Province Science and Technology Cooperation Project, grant number ZDYF2019204; and the General Program from the National Natural Science Foundation of China, grant number 41977200.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We gratefully acknowledge Yinhua Lu (College of Life Sciences, Shanghai Normal University) and Xiuhua Pang (School of Life Sciences, Shandong University) for their valuable support regarding host strains, plasmids and research suggestions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Helynck, G.; Dubertret, C.; Mayaux, J.F.; Leboul, J. Isolation of RP 71955, a new anti-HIV-1 peptide secondary metabolite. J. Antibiot. 1993, 46, 1756–1757. [Google Scholar] [CrossRef] [PubMed]
  2. Fréchet, D.; Guitton, J.D.; Herman, F.; Faucher, D.; Helynck, G.; Monegier du Sorbier, B.; Ridoux, J.P.; James-Surcouf, E.; Vuilhorgne, M. Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus. Biochemistry 1994, 33, 42–50. [Google Scholar] [CrossRef] [PubMed]
  3. Potterat, O.; Stephan, H.; Metzger, J.W.; Gnau, V.; Zähner, H.; Jung, G. Aborycin—A tricyclic 21-peptide antibiotic isolated from Streptomyces griseoflavus. Liebigs Ann. Chem. 1994, 1994, 741–743. [Google Scholar] [CrossRef]
  4. Shao, M.; Ma, J.; Li, Q.; Ju, J. Identification of the anti-infective aborycin biosynthetic gene cluster from deep-sea-derived Streptomyces sp. SCSIO ZS0098 enables production in a heterologous host. Mar. Drugs 2019, 17, 127. [Google Scholar] [CrossRef] [PubMed]
  5. Liu, T.; Huang, Z.; Gui, X.; Xiang, W.; Jin, Y.; Chen, J.; Zhao, J. Multi-omics comparative analysis of Streptomyces mutants obtained byiterative atmosphere and room-temperature plasma mutagenesis. Front. Microbiol. 2020, 11, 630309. [Google Scholar] [CrossRef]
  6. Goel, N.; Singh, R.; Sood, S.; Khare, S.K. Investigation of Streptomyces sp. strain EMB24 secondary metabolite profile has unraveled its extraordinary antibacterial potency against drug-resistant bacteria. Mar. Biotechnol. 2022, 24, 1168–1175. [Google Scholar] [CrossRef]
  7. Maksimov, M.O.; Pan, S.J.; James Link, A. Lasso peptides: Structure, function, biosynthesis, and engineering. Nat. Prod. Rep. 2012, 29, 996–1006. [Google Scholar] [CrossRef]
  8. Duan, Y.; Niu, W.; Pang, L.; Bian, X.; Zhang, Y.; Zhong, G. Unusual Post-Translational Modifications in the Biosynthesis of Lasso Peptides. Int. J. Mol. Sci. 2022, 23, 7231. [Google Scholar] [CrossRef]
  9. Arnison, P.G.; Bibb, M.J.; Bierbaum, G.; Bowers, A.A.; Bugni, T.S.; Bulaj, G.; Camarero, J.A.; Campopiano, D.J.; Challis, G.L.; Clardy, J.; et al. Ribosomally synthesized and post-translationally modified peptide natural products: Overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 2013, 30, 108–160. [Google Scholar] [CrossRef]
  10. Zdouc, M.M.; van der Hooft, J.J.J.; Medema, M.H. Metabolome-guided genome mining of RiPP natural products. Trends Pharmacol. Sci. 2023, 44, 532–541. [Google Scholar] [CrossRef]
  11. Hegemann, J.D.; Zimmermann, M.; Xie, X.; Marahiel, M.A. Lasso peptides: An intriguing class of bacterial natural products. Acc. Chem. Res. 2015, 48, 1909–1919. [Google Scholar] [CrossRef] [PubMed]
  12. Knappe, T.A.; Manzenrieder, F.; Mas-Moruno, C.; Linne, U.; Sasse, F.; Kessler, H.; Xie, X.; Marahiel, M.A. Introducing lasso peptides as molecular scaffolds for drug design: Engineering of an integrin antagonist. Angew. Chem. Int. Ed. Engl. 2011, 50, 8714–8717. [Google Scholar] [CrossRef] [PubMed]
  13. Piscotta, F.J.; Tharp, J.M.; Liu, W.R.; Link, A.J. Expanding the chemical diversity of lasso peptide MccJ25 with genetically encoded noncanonical amino acids. Chem. Commun. 2015, 51, 409–412. [Google Scholar] [CrossRef] [PubMed]
  14. Zong, C.; Maksimov, M.O.; Link, A.J. Construction of lasso peptide fusion proteins. ACS Chem. Biol. 2016, 11, 61–68. [Google Scholar] [CrossRef]
  15. Cheng, C.; Hua, Z.C. Lasso peptides: Heterologous production and potential medical application. Front. Bioeng. Biotechnol. 2020, 8, 571165. [Google Scholar] [CrossRef]
  16. Knappe, T.A.; Linne, U.; Zirah, S.; Rebuffat, S.; Xie, X.; Marahiel, M.A. Isolation and structural characterization of capistruin, a lasso peptide predicted from the genome sequence of Burkholderia thailandensis E264. J. Am. Chem. Soc. 2008, 130, 11446–11454. [Google Scholar] [CrossRef]
  17. Tietz, J.I.; Schwalen, C.J.; Patel, P.S.; Maxson, T.; Blair, P.M.; Tai, H.C.; Zakai, U.I.; Mitchell, D.A. A new genome-mining tool redefines the lasso peptide biosynthetic landscape. Nat. Chem. Biol. 2017, 13, 470–478. [Google Scholar] [CrossRef]
  18. Stariha, L.M.; McCafferty, D.G. Discovery of the class I antimicrobial lasso peptide arcumycin. Chembiochem Eur. J. Chem. Biol. 2021, 22, 2632–2640. [Google Scholar] [CrossRef]
  19. Palazzotto, E.; Tong, Y.; Lee, S.Y.; Weber, T. Synthetic biology and metabolic engineering of actinomycetes for natural product discovery. Biotechnol. Adv. 2019, 37, 107366. [Google Scholar] [CrossRef]
  20. Myronovskyi, M.; Luzhetskyy, A. Heterologous production of small molecules in the optimized Streptomyces hosts. Nat. Prod. Rep. 2019, 36, 1281–1294. [Google Scholar] [CrossRef]
  21. Li, Y.; Ducasse, R.; Zirah, S.; Blond, A.; Goulard, C.; Lescop, E.; Giraud, C.; Hartke, A.; Guittet, E.; Pernodet, J.L.; et al. Characterization of sviceucin from Streptomyces provides insight into enzyme exchangeability and disulfide bond formation in lasso peptides. ACS Chem. Biol. 2015, 10, 2641–2649. [Google Scholar] [CrossRef] [PubMed]
  22. Mevaere, J.; Goulard, C.; Schneider, O.; Sekurova, O.N.; Ma, H.; Zirah, S.; Afonso, C.; Rebuffat, S.; Zotchev, S.B.; Li, Y. An orthogonal system for heterologous expression of actinobacterial lasso peptides in Streptomyces hosts. Sci. Rep. 2018, 8, 8232. [Google Scholar] [CrossRef] [PubMed]
  23. Cobb, R.E.; Wang, Y.; Zhao, H. High-efficiency multiplex genome editing of Streptomyces species using an engineered CRISPR/Cas system. ACS Synth. Biol. 2015, 4, 723–728. [Google Scholar] [CrossRef] [PubMed]
  24. Huang, H.; Zheng, G.; Jiang, W.; Hu, H.; Lu, Y. One-step high-efficiency CRISPR/Cas9-mediated genome editing in Streptomyces. Acta Biochim. Biophys. Sin. 2015, 47, 231–243. [Google Scholar] [CrossRef]
  25. Li, L.; Zheng, G.; Chen, J.; Ge, M.; Jiang, W.; Lu, Y. Multiplexed site-specific genome engineering for overproducing bioactive secondary metabolites in actinomycetes. Metab. Eng. 2017, 40, 80–92. [Google Scholar] [CrossRef]
  26. Feng, Z.; Ogasawara, Y.; Nomura, S.; Dairi, T. Biosynthetic gene cluster of a d-tryptophan-containing lasso peptide, MS-271. Chembiochem Eur. J. Chem. Biol. 2018, 19, 2045–2048. [Google Scholar] [CrossRef]
  27. Kim, M.W.; Lee, B.R.; You, S.; Kim, E.J.; Kim, J.N.; Song, E.; Yang, Y.H.; Hwang, D.; Kim, B.G. Transcriptome analysis of wild-type and afsS deletion mutant strains identifies synergistic transcriptional regulator of afsS for a high antibiotic-producing strain of Streptomyces coelicolor A3(2). Appl. Microbiol. Biotechnol. 2018, 102, 3243–3253. [Google Scholar] [CrossRef]
  28. Kang, S.H.; Huang, J.; Lee, H.N.; Hur, Y.A.; Cohen, S.N.; Kim, E.S. Interspecies DNA microarray analysis identifies WblA as a pleiotropic down-regulator of antibiotic biosynthesis in Streptomyces. J. Bacteriol. 2007, 189, 4315–4319. [Google Scholar] [CrossRef]
  29. Lee, H.N.; Huang, J.; Im, J.H.; Kim, S.H.; Noh, J.H.; Cohen, S.N.; Kim, E.S. Putative TetR family transcriptional regulator SCO1712 encodes an antibiotic downregulator in Streptomyces coelicolor. Appl. Environ. Microbiol. 2010, 76, 3039–3043. [Google Scholar] [CrossRef]
  30. Zheng, G.; Liu, P.; He, W.; Tao, H.; Yang, Z.; Sun, C.; Wang, W.; Lu, Y.; Jiang, W. Identification of the cognate response regulator of the orphan histidine kinase OhkA involved in both secondary metabolism and morphological differentiation in Streptomyces coelicolor. Appl. Microbiol. Biotechnol. 2021, 105, 5905–5914. [Google Scholar] [CrossRef]
  31. Tsypik, O.; Makitrynskyy, R.; Bera, A.; Song, L.; Wohlleben, W.; Fedorenko, V.; Ostash, B. Role of GntR family regulatory gene SCO1678 in gluconate metabolism in Streptomyces coelicolor M145. BioMed Res. Int. 2017, 2017, 9529501. [Google Scholar] [CrossRef] [PubMed]
  32. Montalbán-López, M.; Scott, T.A.; Ramesh, S.; Rahman, I.R.; van Heel, A.J.; Viel, J.H.; Bandarian, V.; Dittmann, E.; Genilloud, O.; Goto, Y.; et al. New developments in RiPP discovery, enzymology and engineering. Nat. Prod. Rep. 2021, 38, 130–239. [Google Scholar] [CrossRef] [PubMed]
  33. Manderscheid, N.; Bilyk, B.; Busche, T.; Kalinowski, J.; Paululat, T.; Bechthold, A.; Petzke, L.; Luzhetskyy, A. An influence of the copy number of biosynthetic gene clusters on the production level of antibiotics in a heterologous host. J. Biotechnol. 2016, 232, 110–117. [Google Scholar] [CrossRef] [PubMed]
  34. Pyeon, H.R.; Nah, H.J.; Kang, S.H.; Choi, S.S.; Kim, E.S. Heterologous expression of pikromycin biosynthetic gene cluster using Streptomyces artificial chromosome system. Microb. Cell Factories 2017, 16, 96. [Google Scholar] [CrossRef]
  35. Zhao, Y.; Li, G.; Chen, Y.; Lu, Y. Challenges and advances in genome editing technologies in Streptomyces. Biomolecules 2020, 10, 734. [Google Scholar] [CrossRef]
  36. Martín, J.F.; Rodríguez-García, A.; Liras, P. The master regulator PhoP coordinates phosphate and nitrogen metabolism, respiration, cell differentiation and antibiotic biosynthesis: Comparison in Streptomyces coelicolor and Streptomyces avermitilis. J. Antibiot. 2017, 70, 534–541. [Google Scholar] [CrossRef]
  37. Fowler-Goldsworthy, K.; Gust, B.; Mouz, S.; Chandra, G.; Findlay, K.C.; Chater, K.F. The actinobacteria-specific gene wblA controls major developmental transitions in Streptomyces coelicolor A3(2). Microbiology 2011, 157, 1312–1328. [Google Scholar] [CrossRef]
  38. Nah, H.J.; Park, J.; Choi, S.; Kim, E.S. WblA, a global regulator of antibiotic biosynthesis in Streptomyces. J. Ind. Microbiol. Biotechnol. 2021, 48, kuab007. [Google Scholar] [CrossRef]
  39. Kim, S.H.; Lee, H.N.; Kim, H.J.; Kim, E.S. Transcriptome analysis of an antibiotic downregulator mutant and synergistic Actinorhodin stimulation via disruption of a precursor flux regulator in Streptomyces coelicolor. Appl. Environ. Microbiol. 2011, 77, 1872–1877. [Google Scholar] [CrossRef]
  40. Hoskisson, P.A.; Rigali, S. Chapter 1: Variation in form and function the helix-turn-helix regulators of the GntR superfamily. Adv. Appl. Microbiol. 2009, 69, 1–22. [Google Scholar] [CrossRef]
  41. Smanski, M.J.; Peterson, R.M.; Rajski, S.R.; Shen, B. Engineered Streptomyces platensis strains that overproduce antibiotics platensimycin and platencin. Antimicrob. Agents Chemother. 2009, 53, 1299–1304. [Google Scholar] [CrossRef] [PubMed]
  42. Xia, H.; Zhan, X.; Mao, X.M.; Li, Y.Q. The regulatory cascades of antibiotic production in Streptomyces. World J. Microbiol. Biotechnol. 2020, 36, 13. [Google Scholar] [CrossRef]
  43. Bierman, M.; Logan, R.; O’Brien, K.; Seno, E.T.; Rao, R.N.; Schoner, B.E. Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene 1992, 116, 43–49. [Google Scholar] [CrossRef] [PubMed]
  44. Kieser, T.; Bibb, M.J.; Buttner, M.J.; Chater, K.F.; Hopwood, D.A. Practical Streptomyces Genetics; John Innes Foundation: Norwich, UK, 2000. [Google Scholar]
  45. Pluskal, T.; Castillo, S.; Villar-Briones, A.; Oresic, M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinform. 2010, 11, 395. [Google Scholar] [CrossRef] [PubMed]
  46. Muth, G.; Nußbaumer, B.; Wohlleben, W.; Pühler, A. A vector system with temperature-sensitive replication for gene disruption and mutational cloning in Streptomycetes. Mol. Gen. Genet. MGG 1989, 219, 341–348. [Google Scholar] [CrossRef]
  47. MacNeil, D.J.; Gewain, K.M.; Ruby, C.L.; Dezeny, G.; Gibbons, P.H.; MacNeil, T. Analysis of Streptomyces avermitilis genes required for avermectin biosynthesis utilizing a novel integration vector. Gene 1992, 111, 61–68. [Google Scholar] [CrossRef]
  48. Gomez-Escribano, J.P.; Bibb, M.J. Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters. Microb. Biotechnol. 2011, 4, 207–215. [Google Scholar] [CrossRef]
  49. Kaweewan, I.; Hemmi, H.; Komaki, H.; Harada, S.; Kodani, S. Isolation and structure determination of a new lasso peptide specialicin based on genome mining. Bioorg. Med. Chem. 2018, 26, 6050–6055. [Google Scholar] [CrossRef]
  50. Vinogradov, A.A.; Suga, H. Introduction to thiopeptides: Biological activity, biosynthesis, and strategies for functional reprogramming. Cell Chem. Biol. 2020, 27, 1032–1051. [Google Scholar] [CrossRef]
  51. Georgiou, M.A.; Dommaraju, S.R.; Guo, X.; Mast, D.H.; Mitchell, D.A. Bioinformatic and Reactivity-Based Discovery of Linaridins. ACS Chem. Biol. 2020, 15, 2976–2985. [Google Scholar] [CrossRef]
  52. Sivonen, K.; Leikoski, N.; Fewer, D.P.; Jokela, J. Cyanobactins-ribosomal cyclic peptides produced by cyanobacteria. Appl. Microbiol. Biotechnol. 2010, 86, 1213–1225. [Google Scholar] [CrossRef] [PubMed]
  53. Franz, L.; Kazmaier, U.; Truman, A.W.; Koehnke, J. Bottromycins—Biosynthesis, synthesis and activity. Nat. Prod. Rep. 2021, 38, 1659–1683. [Google Scholar] [CrossRef] [PubMed]
  54. Do Amaral, S.C.; Monteiro, P.R.; Neto, J.; Serra, G.M.; Gonçalves, E.C.; Xavier, L.P.; Santos, A.V. Current knowledge on microviridin from Cyanobacteria. Mar. Drugs 2021, 19, 17. [Google Scholar] [CrossRef] [PubMed]
  55. Singh, V.; Rao, A. Distribution and diversity of glycocin biosynthesis gene clusters beyond Firmicutes. Glycobiology 2021, 31, 89–102. [Google Scholar] [CrossRef]
  56. Duquesne, S.; Destoumieux-Garzón, D.; Peduzzi, J.; Rebuffat, S. Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat. Prod. Rep. 2007, 24, 708–734. [Google Scholar] [CrossRef]
Figure 1. General information on aborycin and siamycin-I and their BGCs, sequences and secondary structures. Sequence differences between aborycin and siamycin-I are marked in red.
Figure 1. General information on aborycin and siamycin-I and their BGCs, sequences and secondary structures. Sequence differences between aborycin and siamycin-I are marked in red.
Marinedrugs 21 00534 g001
Figure 2. Extraction of aborycin. (A). The extraction procedure. (B). The 23.2 min HPLC peaks of extractives obtained from the supernatant of M1346::3gul by butanone or by macroporous adsorption resins. Siamycin-I was used as a control. The loading quantities of each test were adjusted to represent the same amount of the supernatant. (C). Mass spectrum analysis of the matter abundance in the m/z range [150–2000] of the 23.2 min collection from the sample enriched by the AB-8 resin. A peak at m/z = 1082.43 (z = 2) accounted for approximately 90% of the total mass. (D). The standard curve of concentrations of the HPLC peak areas of aborycin.
Figure 2. Extraction of aborycin. (A). The extraction procedure. (B). The 23.2 min HPLC peaks of extractives obtained from the supernatant of M1346::3gul by butanone or by macroporous adsorption resins. Siamycin-I was used as a control. The loading quantities of each test were adjusted to represent the same amount of the supernatant. (C). Mass spectrum analysis of the matter abundance in the m/z range [150–2000] of the 23.2 min collection from the sample enriched by the AB-8 resin. A peak at m/z = 1082.43 (z = 2) accounted for approximately 90% of the total mass. (D). The standard curve of concentrations of the HPLC peak areas of aborycin.
Marinedrugs 21 00534 g002
Figure 3. Aborycin titers from different strains. HNS054, the wild-type strain Streptomyces sp. HNS054. ΔphoUΔgntR, gene knockout strains from S. coelicolor M1346::3gul. Orange block, average production from supernatant extracted by the AB-8 method. Blue block, average production from mycelia extracted by the methanol method. Error bar, standard deviation of total titers (supernatant + mycelia). Data were counted from triplicate experiments. ***, p < 0.001. n.s., p > 0.05.
Figure 3. Aborycin titers from different strains. HNS054, the wild-type strain Streptomyces sp. HNS054. ΔphoUΔgntR, gene knockout strains from S. coelicolor M1346::3gul. Orange block, average production from supernatant extracted by the AB-8 method. Blue block, average production from mycelia extracted by the methanol method. Error bar, standard deviation of total titers (supernatant + mycelia). Data were counted from triplicate experiments. ***, p < 0.001. n.s., p > 0.05.
Marinedrugs 21 00534 g003
Figure 4. The growth of strains on MS-agar plates from 3 days to 9 days. ΔphoUΔgntR, gene knockout strains from S. coelicolor M1346::3gul.
Figure 4. The growth of strains on MS-agar plates from 3 days to 9 days. ΔphoUΔgntR, gene knockout strains from S. coelicolor M1346::3gul.
Marinedrugs 21 00534 g004
Table 1. Information on the genes to be knocked out.
Table 1. Information on the genes to be knocked out.
Trial Gene Code Symbol Relevant Features References
J01 SCO4228phoUΔphoU mutant showed 6-fold increase in ACT production when phosphate starvation[27]
J04 SCO3579wblAΔwblA mutant showed 1.5-fold increase in doxorubicin production[28]
J05 SCO1712SCO1712ΔSCO1712 mutant showed 1.62-fold or 1.22-fold increase in ACT or RED production, respectively[29]
J07 SCO3008orrAΔorrA mutant showed great increase in ACT and RED production[30]
J08 SCO1678gntRΔgntR mutant altered the secondary metabolite profile of S. coelicolor[31]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, J.-Y.; Liang, J.-Y.; Liu, Z.-Y.; Yi, Y.-Z.; Zhao, J.; Huang, Z.-Y.; Chen, J. Multicopy Chromosome Integration and Deletion of Negative Global Regulators Significantly Increased the Heterologous Production of Aborycin in Streptomyces coelicolor. Mar. Drugs 2023, 21, 534. https://doi.org/10.3390/md21100534

AMA Style

Li J-Y, Liang J-Y, Liu Z-Y, Yi Y-Z, Zhao J, Huang Z-Y, Chen J. Multicopy Chromosome Integration and Deletion of Negative Global Regulators Significantly Increased the Heterologous Production of Aborycin in Streptomyces coelicolor. Marine Drugs. 2023; 21(10):534. https://doi.org/10.3390/md21100534

Chicago/Turabian Style

Li, Jia-Yi, Jun-Yu Liang, Zhao-Yuan Liu, Yue-Zhao Yi, Jing Zhao, Zhi-Yong Huang, and Jun Chen. 2023. "Multicopy Chromosome Integration and Deletion of Negative Global Regulators Significantly Increased the Heterologous Production of Aborycin in Streptomyces coelicolor" Marine Drugs 21, no. 10: 534. https://doi.org/10.3390/md21100534

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop